Carboplatin

Primary Uses

Carboplatin is a chemotherapy drug used to treat cancer. Its main approved use is for advanced ovarian cancer.

Healthcare providers typically prescribe carboplatin in two main scenarios:

• First-line treatment: It is used as an initial therapy for advanced ovarian cancer, usually in combination with other cancer-fighting medications.
• Recurrent cancer: It is used to treat ovarian cancer that has returned or progressed after a patient has already completed other chemotherapy treatments.

As a cancer medicine, carboplatin works by slowing or stopping the growth of cancer cells. It is administered by a healthcare professional in a medical setting, such as a hospital or clinic.

Mechanism of Action

Carboplatin belongs to a class of drugs known as platinum-containing compounds. It is often referred to as an alkylating agent. These medications work by targeting the DNA inside cells, which contains the instructions for cell growth and division.

Once carboplatin enters a cancer cell, it undergoes a chemical reaction that allows it to bind to the cell's DNA. This process creates cross-links, which are structural bonds that prevent the DNA strands from separating or being copied correctly. When the DNA is damaged in this way, the cell cannot produce the proteins it needs to survive or create new cells.

Key aspects of how carboplatin works include:

• DNA Interference: It disrupts the cell's genetic code, making it impossible for the cell to repair itself.
• Cell Death: When the damage to the DNA becomes too severe, the cancer cell receives a signal to stop growing and eventually dies.
• Non-Specific Action: Carboplatin is considered cell-cycle non-specific, meaning it can attack cancer cells at various stages of their life cycle, whether they are actively dividing or in a resting phase.

Because cancer cells typically divide faster than healthy cells, they are more sensitive to the DNA damage caused by carboplatin. However, the drug can also affect some healthy cells in the body that divide quickly, which is why side effects occur.

Common Side Effects

Carboplatin often affects rapidly dividing cells, which can lead to various physical changes. Common side effects include:

• Nausea and vomiting
• Diarrhea, constipation, or stomach pain
• Loss of appetite and weight loss
• General weakness or fatigue
• Temporary hair loss
• Mouth sores or inflammation
• Changes in the sense of taste
• Tingling, burning, or numbness in the hands or feet

Serious Side Effects

Seek medical attention immediately if you notice symptoms of a serious reaction or complication, such as:

• Signs of infection, including fever, chills, or persistent sore throat
• Unusual bleeding or bruising
• Shortness of breath, dizziness, or pale skin
• Allergic reactions, such as rash, hives, itching, or swelling of the face, lips, or tongue
• Wheezing or difficulty breathing
• Vision loss or other changes in eyesight
• Ringing in the ears or hearing loss
• Decreased urination or blood in the urine

Boxed Warnings

Carboplatin has boxed warnings for the following serious conditions:

• Bone marrow suppression: This medication can significantly lower the number of blood cells produced by the bone marrow. This may lead to an increased risk of infection, anemia, and bleeding problems. Blood counts usually reach their lowest point between 14 and 21 days after treatment.
• Hypersensitivity reactions: Severe, life-threatening allergic reactions can occur. These reactions may happen within minutes of receiving the infusion, especially in patients who have previously received platinum-based chemotherapy.
• Vomiting: Severe nausea and vomiting are common and may require medication for prevention or management.

Precautions and Monitoring

Healthcare providers typically monitor patients closely for the following:

• Blood counts: Frequent blood tests are required to check levels of white blood cells, red blood cells, and platelets. Treatment may be delayed or the dose adjusted if these levels are too low.
• Kidney function: Carboplatin can affect how the kidneys work. Monitoring kidney function through blood tests is necessary, particularly for patients with pre-existing kidney issues or those receiving other medications that affect the kidneys.
• Neurological and hearing changes: While less common than with similar drugs, carboplatin can cause nerve damage (peripheral neuropathy) or hearing loss (ototoxicity). Hearing tests may be recommended, especially for pediatric patients.

Contraindications

Carboplatin is generally not used in individuals with:

• A history of severe allergic reactions to carboplatin or other platinum-containing medications, such as cisplatin.
• Severe bone marrow suppression.
• Significant active bleeding.

Pregnancy and Breastfeeding

Carboplatin can cause fetal harm if administered during pregnancy. Effective contraception is recommended for both men and women during treatment and for a specified period afterward. Breastfeeding is generally not recommended while receiving this medication because of the potential for serious adverse reactions in the infant.

Pregnancy

Carboplatin can cause fetal harm when administered to a pregnant person. Research in animals has shown that the drug can lead to birth defects and may be toxic to a developing embryo. Because of these risks, healthcare providers typically advise against starting or continuing carboplatin during pregnancy unless the potential benefit justifies the potential risk to the fetus.

Precautions for individuals of reproductive potential include:

• Using effective birth control methods during treatment and for a period of time after the final dose.
• Notifying a healthcare provider immediately if pregnancy occurs or is suspected.
• Discussing the potential impact on future fertility with a doctor before beginning treatment.

Breastfeeding

It is not known whether carboplatin passes into human breast milk. However, because many drugs are excreted in milk and because carboplatin can cause serious adverse reactions in infants, breastfeeding is generally not recommended during treatment. Patients should talk with their healthcare team to weigh the risks and benefits and decide on the best infant feeding plan.

Available Forms

Carboplatin is available in the following forms for intravenous administration:

• Injectable Solution: A clear liquid ready for dilution and infusion.
• Lyophilized Powder: A sterile powder that must be mixed with a liquid before it can be administered.

This medication is intended for use in a clinical setting and is delivered directly into the bloodstream through an infusion.

FDA Approval and Indications

Carboplatin is approved by the U.S. Food and Drug Administration (FDA) for the treatment of advanced ovarian carcinoma. It is used both as a primary treatment in combination with other chemotherapy drugs and as a secondary treatment for patients whose cancer has returned after previous therapy.

Boxed Warnings

The FDA has issued several boxed warnings for carboplatin due to the risk of severe adverse reactions. These warnings include:

• Bone Marrow Suppression: Carboplatin can cause a significant decrease in blood cell production. This may lead to severe anemia, increased risk of infection, and bleeding complications. These effects are usually related to the dosage administered.
• Anaphylactic-like Reactions: Severe allergic reactions have been reported with carboplatin use. These reactions can occur within minutes of administration, even in patients who have previously tolerated the drug without issues.
• Vomiting: The medication is known to cause significant nausea and vomiting, which may require medical management.

Administration and Safety Requirements

Due to its toxicity and the potential for serious complications, the FDA requires that carboplatin be administered only under the supervision of a physician experienced in the use of cancer chemotherapy agents. Treatment must take place in a facility equipped to manage severe allergic reactions and other emergencies. Healthcare providers must perform regular blood tests to monitor kidney function and blood cell counts throughout the course of treatment.

FDA-Approved Indications

The U.S. Food and Drug Administration (FDA) has approved carboplatin for the following primary uses:

• Initial Treatment of Ovarian Cancer: Carboplatin is indicated for the treatment of advanced ovarian carcinoma in combination with other approved chemotherapeutic agents, such as cyclophosphamide.
• Recurrent Ovarian Cancer: It is approved as a single-agent therapy for patients with recurrent ovarian carcinoma who have previously received chemotherapy, including those who have been treated with cisplatin.

FDA Boxed Warnings

The FDA has issued several boxed warnings for carboplatin due to the risk of severe side effects:

• Bone Marrow Suppression: Carboplatin can cause a significant decrease in blood cell production. This may lead to low white blood cell counts (increasing infection risk), low red blood cell counts (anemia), and low platelet counts (increasing bleeding risk).
• Anaphylactic Reactions: Severe allergic reactions have been reported with carboplatin use. These reactions can occur within minutes of administration and may happen even if a patient has tolerated previous doses.
• Supervision Requirements: The FDA requires that carboplatin be administered only under the supervision of a physician experienced in the use of cancer chemotherapy agents.

Other Regulatory Information

While the primary FDA-approved indication is for ovarian cancer, healthcare providers may use carboplatin for other types of cancer based on clinical guidelines and research. This is known as off-label use. The drug is administered intravenously, and dosage is typically calculated based on the patient's kidney function and desired blood concentration levels.